

## NeurogesX, Inc. (NGSX) – NGX-4010: Market Assessment

Gauging logistics, procedural pain, off-label use, and reimbursement issues

### A survey among 32 Physicians

#### Study Description

Methodology	Online survey
Data collection period	March 7-12, 2008
Survey audience	Anesthesiologists (n = 15) Neurologists (n = 17)

Results segmented by physicians with and without perceived logistical barriers for using NGX-4010:

- Perceived insufficient time or facilities, “iTF” (n = 10)
- Perceived sufficient time or facilities, “sTF” (n = 22)

#### Study Objectives

Decision Metrics surveyed Anesthesiologists and Neurologists to investigate the anticipated level of adoption of NGX-4010 by the medical community based on product features and benefits. Specifically, we explored four areas identified by investors as primary concerns regarding the potential level of acceptance and usage of NGX-4010 among physicians in the localized neuropathic pain market.

- Understand procedural logistics:
  - Assess practice resources (time, personnel, office space) to accommodate patients for the NGX-4010 procedure
- Gauge procedural pain:
  - Understand physician perspectives on patients’ willingness to undergo the procedure with the possibility of treatment-related discomfort
- Investigate expected off-label use:
  - Assess the frequency of use for treating various conditions, irrespective of the labeled indication, if NGX-4010 received a label limited to a particular condition
- Assess reimbursement issues:
  - Explore the potential effects of Medicare Part B reimbursement and compensation for physicians’ time on the anticipated usage of NGX-4010

#### Companies and Products Mentioned in This Report

Company	Ticker Symbol	Product
NeurogesX, Inc.	NGSX	NGX-4010

For additional information on this study or to purchase this report, please contact:

Dan Meichenbaum

Phone: 415.263.6628; Email: dan.meichenbaum@wedbush.com